Liraglutide
Liraglutide is a once-daily GLP-1 receptor agonist approved in the United States under different brand names for type 2 diabetes and for chronic weight management. Its trial record includes cardiovascular outcome data, and it shares the gastrointestinal side effect profile of the class.
Evidence-first summary of liraglutide, a daily GLP-1 receptor agonist: clinical trial record, FDA approval status, side effects and unresolved questions.
The earlier daily GLP-1 medicine, and a useful reference point for the class.
Key takeaways
- Once-daily injection, unlike the weekly newer agents.
- Approved for both glycaemic and weight-related indications under different brands.
- Cardiovascular outcome trial data exists for the diabetes population studied.
- Largely superseded in practice by longer-acting agents, but well documented.
Where it sits in the class
Liraglutide arrived before the weekly agents and demonstrated that sustained GLP-1 receptor activation could improve glucose control and reduce weight. Daily injection is the main practical difference from newer options.
What the evidence covers
Randomised trials in diabetes and weight management, plus a cardiovascular outcome trial in a high-risk diabetes population. As with all approved medicines, benefits and harms are defined for the studied populations rather than universally.
Practical framing
Whether an older daily agent or a newer weekly one is appropriate is a clinical decision involving indication, tolerance, cost and monitoring.
Beiing does not publish dosages, schedules, administration instructions, combinations or sourcing guidance for this or any other compound.
Frequently asked questions
Is liraglutide less effective than newer GLP-1 medicines?
Trials of newer agents have generally reported larger average weight effects, but direct comparison depends on head-to-head studies and the population being treated.
Why is it taken daily?
Its molecular design extends action to roughly 24 hours, unlike the week-long agents.
Does it have cardiovascular evidence?
A cardiovascular outcome trial was conducted in a high-risk type 2 diabetes population; results apply to that population.
Related on Beiing
- Peptides and metabolic health - The incretin system.
- Approved peptide medicines - What approval means.
- How Beiing rates peptide evidence - The five evidence levels used in this section.
- Peptides & Human Biology - The hub for every page in this section.
Sources
- FDA - Drug Approvals and Databases - U.S. Food and Drug Administration
- ClinicalTrials.gov - U.S. National Library of Medicine
- PubMed - National Library of Medicine - NIH
Written by Beiing Editorial Team · Editorially reviewed by Research & Regulatory Review Desk · Published · Last reviewed . Editorial and research review by Beiing writers and researchers. This is not medical or clinical review, and no clinician signs off on our content.
Educational content only - not medical advice. In a crisis, call or text 988 (US) or your local emergency number. See crisis resources.